Sigyn Therapeutics (SIGY) Non-Current Assets (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Non-Current Assets of $50000.0 for Q3 2025, little changed sequentially from $50000.0 in Q2 2025, and down 68.42% YoY from $158330.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Non-Current Assets (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Non-Current Assets for 10 years, with the latest figure at $50000.0 in Q3 2025.
- Quarterly Non-Current Assets fell 68.42% year-over-year to $50000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $468689.0 (down 35.33% YoY) and the FY2024 annual result came in at $192475.0, down 5.53% from the prior year.
- Non-Current Assets held at $50000.0 in Q3 2025 per SIGY's latest filing, from $50000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $324291.0 in Q3 2021 and troughed at $15806.0 in Q1 2021.
- A 5-year average of $210704.9 and a median of $218352.0 in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 1821.95% in 2022, then tumbled 71.23% in 2025.
- Over 5 years, Non-Current Assets stood at $317228.0 in 2021, then dropped by 17.23% to $262581.0 in 2022, then dropped by 22.41% to $203743.0 in 2023, then fell by 5.53% to $192475.0 in 2024, then slumped by 74.02% to $50000.0 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $50000.0, $50000.0, and $176214.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 50,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 176,214.00 |
| Dec 31, 2024 | 192,475.00 |
| Sep 30, 2024 | 158,330.00 |
| Jun 30, 2024 | 173,789.00 |
| Mar 31, 2024 | 188,867.00 |
| Dec 31, 2023 | 203,743.00 |
| Sep 30, 2023 | 218,352.00 |
| Jun 30, 2023 | 233,022.00 |
| Mar 31, 2023 | 247,959.00 |
| Dec 31, 2022 | 262,581.00 |
| Sep 30, 2022 | 276,896.00 |
| Jun 30, 2022 | 290,911.00 |
| Mar 31, 2022 | 303,784.00 |
| Dec 31, 2021 | 317,228.00 |
| Sep 30, 2021 | 324,291.00 |
| Jun 30, 2021 | 319,145.00 |
| Mar 31, 2021 | 15,806.00 |
| Dec 31, 2020 | 23,633.00 |